Biofluid biomarkers for Alzheimer’s disease:past,present,and future  

作　　者：Chengyu An Huimin Cai Ziye Ren Xiaofeng Fu Shuiyue Quan Longfei Jia 

机构地区：[1]Innovation Center for Neurological Disorders and Department of Neurology,Xuanwu Hospital,Capital Medical University,National Clinical Research Center for Geriatric Diseases,Beijing 100053,China

出　　处：《Medical Review》2024年第6期467-491,共25页医学评论(英文)

基　　金：supported by the National Natural Science Foundation of China(Grant Nos.81870825 and 82071194);the Beijing Brain Initiative from the Beijing Municipal Science&Technology Commission(Grant No.Z201100005520016);the Beijing Municipal Natural Science Foundation(Grant No.7202061);the Capital’s Funds for Health Improvement and Research(Grant No.2022-2-2017);the STI 2030-Major Projects(Grant No.2022ZD0211600,2022ZD0211605).

摘　　要：Alzheimer’s disease(AD)is a gradually progressive neurodegenerative disease with tremendous social and economic burden.Therefore,early and accurate diagnosis is imperative for effective treatment or prevention of the disease.Cerebrospinal fluid and blood biomarkers emerge as favorable diagnostic tools due to their relative accessibility and potential for widespread clinical use.This review focuses on the AT(N)biomarker system,which includes biomarkers reflecting AD core pathologies,amyloid deposition,and pathological tau,as well as neurodegeneration.Novel biomarkers associated with inflammation/immunity,synaptic dysfunction,vascular pathology,andα-synucleinopathy,which might contribute to either the pathogenesis or the clinical progression of AD,have also been discussed.Other emerging candidates including non-coding RNAs,metabolites,and extracellular vesicle-based markers have also enriched the biofluid biomarker landscape for AD.Moreover,the review discusses the current challenges of biofluid biomarkers in AD diagnosis and offers insights into the prospective future development.

关 键 词：Alzheimer’s disease BIOMARKER cerebrospinal fluid blood AMYLOID 

分 类 号：R74[医药卫生—神经病学与精神病学]